IRIS
DI RAIMONDO, FRANCESCO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 12.906
EU - Europa 8.639
AS - Asia 2.536
AF - Africa 558
OC - Oceania 24
Continente sconosciuto - Info sul continente non disponibili 19
SA - Sud America 12
Totale 24.694
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 12.076
IE - Irlanda 2.709
UA - Ucraina 2.442
CN - Cina 2.169
IT - Italia 1.665
CA - Canada 823
RU - Federazione Russa 666
CI - Costa d'Avorio 405
SE - Svezia 283
DE - Germania 226
GB - Regno Unito 149
SN - Senegal 137
VN - Vietnam 112
FR - Francia 103
CH - Svizzera 86
IN - India 60
NL - Olanda 55
UZ - Uzbekistan 48
BE - Belgio 46
AT - Austria 44
GR - Grecia 43
PL - Polonia 37
LB - Libano 33
SG - Singapore 30
ES - Italia 21
EU - Europa 19
AU - Australia 17
IR - Iran 17
FI - Finlandia 16
CZ - Repubblica Ceca 15
HK - Hong Kong 14
JP - Giappone 12
NG - Nigeria 10
BG - Bulgaria 8
NO - Norvegia 8
KR - Corea 7
NZ - Nuova Zelanda 7
IL - Israele 5
TR - Turchia 5
BR - Brasile 4
MA - Marocco 4
MX - Messico 4
RS - Serbia 4
AR - Argentina 3
AZ - Azerbaigian 3
LU - Lussemburgo 3
SI - Slovenia 3
TH - Thailandia 3
AE - Emirati Arabi Uniti 2
BD - Bangladesh 2
CL - Cile 2
EG - Egitto 2
KW - Kuwait 2
KZ - Kazakistan 2
MY - Malesia 2
PH - Filippine 2
PT - Portogallo 2
RO - Romania 2
BH - Bahrain 1
BO - Bolivia 1
CO - Colombia 1
EE - Estonia 1
GL - Groenlandia 1
HR - Croazia 1
ID - Indonesia 1
JM - Giamaica 1
JO - Giordania 1
LK - Sri Lanka 1
PA - Panama 1
PY - Paraguay 1
SA - Arabia Saudita 1
SK - Slovacchia (Repubblica Slovacca) 1
TW - Taiwan 1
Totale 24.694
Salva come PNG Salva come JPEG
Città #
Jacksonville 2.708
Dublin 2.692
Chandler 2.210
Catania 785
Nanjing 770
Cambridge 740
Andover 735
Lawrence 734
Toronto 656
Houston 493
Ashburn 434
Des Moines 434
Abidjan 405
San Mateo 401
Boardman 333
Nanchang 272
Wilmington 267
Shenyang 187
Saint Petersburg 184
Hebei 180
Ottawa 151
Jiaxing 150
Dakar 137
Changsha 135
Tianjin 111
Grafing 99
Dong Ket 87
Moscow 61
Beijing 56
Florence 53
Washington 53
Seattle 50
Brussels 45
Hangzhou 44
Rome 41
Den Haag 39
Norwalk 38
Kunming 37
Milan 37
Los Angeles 36
Bremen 32
Falls Church 32
Pune 31
Jinan 26
Hanoi 23
Liberty Lake 21
Ann Arbor 20
Palermo 19
Frankfurt Am Main 18
Redwood City 18
Guangzhou 17
Hanover 17
Ningbo 16
Maracena 15
Taizhou 15
Ludwigshafen 14
Zhengzhou 14
Augusta 13
Edinburgh 12
Ardabil 11
Hong Kong 11
Lappeenranta 11
Lausanne 11
Misterbianco 11
Singapore 11
Abuja 10
Dearborn 10
Mountain View 10
Redmond 10
Bologna 9
Changchun 9
Portland 9
Lanzhou 8
Messina 8
Monmouth Junction 8
Oslo 8
Paris 8
Princeton 8
Turin 8
Leawood 7
Mascalucia 7
Seoul 7
Tappahannock 7
Fukuoka 6
Fuzhou 6
Giardini-Naxos 6
Padova 6
Woodbridge 6
Amsterdam 5
Bari 5
Fremont 5
Hyderabad 5
Lentini 5
London 5
Naples 5
Piazzola Sul Brenta 5
Poltava 5
Tel Aviv 5
Torino 5
Verona 5
Totale 17.760
Salva come PNG Salva come JPEG
Nome #
Prognostic meaning of neutrophil to lymphocyte ratio (NLR) and lymphocyte to monocyte ration (LMR) in newly diagnosed Hodgkin lymphoma patients treated upfront with a PET-2 based strategy 202
Childhood neurofibromatosis type 2 (NF2) and related disorders: From bench to bedside and biologically targeted therapies [Neurofibromatosi tipo 2 (NF2) e sindromi correlate in età infantile: dalla biologia molecolare alla pratica clinica e nuove terapie con farmaci biologici] 192
Baseline factors associated with response to ruxolitinib: An independent study on 408 patients with myelofibrosis 139
α-Lipoic Acid Reduces Iron-induced Toxicity and Oxidative Stress in a Model of Iron Overload 132
Heme oxygenase-1 nuclear translocation regulates bortezomib-induced cytotoxicity and mediates genomic instability in myeloma cells. 107
CXCL12/CXCR4 axis supports mitochondrial trafficking in tumor myeloma microenvironment 96
Heme Oxygenase Inhibition Sensitizes Neuroblastoma Cells to Carfilzomib 89
Multicenter Total Therapy Gimema LAL 1509 Protocol for De Novo Adult Ph plus Acute Lymphoblastic Leukemia (ALL) Patients. Updated Results and Refined Genetic-Based Prognostic Stratification 89
Clinical Implications of Discordant Early Molecular Responses in CML Patients Treated with Imatinib 83
A western blot assay for detecting mutant nucleophosmin (NPM1) proteins in acute myeloid leukaemia 80
Inhibition of TLR4 signaling affects mitochondrial fitness and overcomes bortezomib resistance in myeloma plasma cells 74
Ixazomib improves bone remodeling and counteracts sonic hedgehog signaling inhibition mediated by myeloma cells 65
Mitochondrial Functions, Energy Metabolism and Protein Glycosylation are Interconnected Processes Mediating Resistance to Bortezomib in Multiple Myeloma Cells 63
Bortezomib modulates CHIT1 and YKL40 in monocyte-derived osteoclast and in myeloma cells. 62
Mesenchymal stem cells (MSC) promotes tumor microenvironment transformation driving Granulocyte-like Myeloid Derived Suppressor Cells (G-MDSC) activation in Smoldering and Multiple Myeloma patients 62
Antiproliferative and Antiangiogenic Effects of Punica granatum Juice (PGJ) in Multiple Myeloma (MM) 61
Absence of nucleophosmin leukaemic mutants in B and T cells from AML with NPM1 mutations: implications for the cell of origin of NPMc+ AML 61
Cementoplasty in the management of painful extraspinal bone metastases: our experience 60
A PHASE III STUDY OF ENOXAPARIN VERSUS ASPIRIN VERSUS LOW-DOSE WARFARIN AS THROMBOPROPHYLAXIS FOR PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA TREATED UP-FRONT WITH THALIDOMIDE BASED-REGIMENS 60
The Apoptotic Machinery As A Biological Complex System: Analysis of its Omics and Evolution, Identification of Candidate Genes for Fourteen Types of Cancer and Experimental Validation in CML and Neuroblastoma 59
A snapshot of asparaginase-induced liver insufficiency. 57
A MULTICENTRIC STUDY TO EVALUATE THE EFFICACY OF EPOIETIN ZETA (BIOSIMILAR OF EPO ALPHA) IN LOW RISK MYELODISPLASTIC PATIENTS 57
13q14 deletion size and number of deleted cells both influence prognosis in chronic lymphocytic leukemia 57
Non ABL-directed inhibitors as alternative treatment strategies for chronic myeloid leukemia 57
High BCR-ABL/GUSISlevels at diagnosis of chronic phase CML are associated with unfavorable responses to standard-dose imatinib 57
Angiogenic factors (VEGF, bFGF, and HGF) in multiple myeloma: higher levels in bone marrow than in peripheral blood 56
Immune off-target effects of Brentuximab Vedotin in relapsed/refractory Hodgkin Lymphoma 56
Pegylated asparaginase-induced liver injury, a case-based review and data from pharmacovigilance 56
Unsuccessful dasatinib therapy in a refractory patient with chronic lymphocytic leukemia 55
Clinico-biological features of 5202 patients with acute lymphoblastic leukemia enrolled in the Italian AIEOP and GIMEMA protocols and stratified in age cohorts. 55
Complete Response to First-Line Bortezomib-Thalidomide-Dexamethasone Therapy in Multiple Myeloma Patients with t(4;14): Analysis of Gene Expression Profile 55
Alternation of epirubicin and mitoxantrone in CHOP-like regimens retains efficacy and reduces overall toxicity in elderly patients with high and intermediate grade non-Hodgkin lymphomas 54
Acute pre-hepatic portal thrombosis: diagnosis and therapy 54
PREDICTORS FOR RESPONSE TO RUXOLITINIB IN REAL-LIFE: AN OBSERVATIONAL INDEPENDENT STUDY ON 266 PATIENTS WITH MYELOFIBROSIS 54
NEUTROPHIL TO LYMPHOCYTE RATIO IMPROVES THE RISK ASSESSMENT OF ISS STAGING IN NEWLY DIAGNOSED MM PATIENTS TREATED UPFRONT WITH NOVEL AGENTS 54
A Phase III Study of Enoxaparin Vs Aspirin as Thromboprophylaxis for Newly Diagnosed Myeloma Patients Treated with Lenalidomide-Based Regimen 54
Effects of imatinib mesylate in osteoblastogenesis 53
Suppression of survivin induced by BCR-ABL/JAK2/STAT3 pathway sensitizes imatinib-resistant CML cells to different cytotoxic drugs 53
Bortezomib for the treatment of previously untreated multiple myeloma. 53
NEUTROPHIL TO LYMPHOCYTE RATIO (NLR) IMPROVES THE RISK ASSESSMENT OF ISS STAGING IN NEWLY DIAGNOSED MM PATIENTS TREATED UPFRONT WITH NOVEL AGENTS 53
A population-based study of chronic myeloid leukemia patients treated with imatinib in first line 52
Vg9Vd2 T Lymphocytes Efficiently Recognize and Kill Zoledronate-Sensitized, Imatinib-Sensitive, and Imatinib-Resistant Chronic Myelogenous Leukemia Cells 52
The Apoptotic Machinery As A Biological Complex System: Analysis of its Omics, Identification of Candidate Genes for Fourteen Major Types of Cancer and Experimental Validation in CML and Neuroblastoma 52
AN INSERTION IN THE BCR-ABL KINASE DOMAIN CONTRIBUTES TO IMATINIB MESYLATE RESISTANCE 52
Targeting heme Oxygenase-1 with hybrid compounds to overcome Imatinib resistance in chronic myeloid leukemia cell lines 52
Lymphoma of the cecum: a case report 51
SPARC expression in CML is associated to imatinib treatment and to inhibition of leukemia cell proliferation 51
A Phase III Study of Double Autotransplantation Incorporating Bortezomib-Thalidomide-Dexamethasone (VTD) or Thalidomide-Dexamethasone (TD) for Multiple Myeloma: Superior Clinical Outcomes with VTD Compared to TD 51
The apoptotic machinery as a biological complex system: analysis of its omics and evolution, identification of candidate genes for fourteen major types of cancer, and experimental validation in CML and neuroblastoma 51
BCR-ABL1 doubling-times and halving-times may predict CML response to tyrosine kinase inhibitors 51
Chk1 Inhibition Restores Inotuzumab Ozogamicin Citotoxicity in CD22-Positive Cells Expressing Mutant p53 51
ABL1-Directed Inhibitors for CML: Efficacy, Resistance and Future Perspectives 51
Lithium and acute myeloid leukemia. 50
The Apoptotic Machinery As A Biological Complex System: Analysis Of Its Omics And Evolution, Identification Of Candidate Genes For Fourteen Major Types Of Cancer And Experimental Validation in CML And Neuroblastoma 50
Clinical and Endoscopic Presentation of Primary Gastric Lymphoma: An Italian Multicenter Study 50
Hypoxia Induces Imatinib Resistance in CML Cell Lines 50
Rate of fungal infections in patients with acute myeloid leukemia during induction treatment performing two prophylactic strategies: preliminary results 50
TLR4 signaling drives mesenchymal stromal cells commitment to promote tumor microenvironment transformation in multiple myeloma 50
SMOLDERING MYELOMA: WALKING THROUGH RISK FACTORS AND TENTATIVE CLASSIFICATION SYSTEMS 49
Peripheral blood stem cell contamination evaluated by a highly sensitive molecular method fails to predict outcome of autotransplanted multiple myeloma patients 49
Broad copy neutral-loss of heterozygosity regions and rare recurring copy number abnormalities in normal karyotype-acute myeloid leukemia genomes 49
Multidrug resistance mechanisms in chronic lymphocytic leukaemia 49
ARGINASE 1 IS A MARKER OF MYELOID-MEDIATED IMMUNOSUPPRESSION WITH PROGNOSTIC MEANING IN CLASSIC HODGKIN'S LYMPHOMA 49
The EUTOS population-based registry: incidence and clinical characteristics of 2904 CML patients in 20 European Countries 49
A PHASE 3, RANDOMIZED CLINICAL STUDY OF AUTOLOGOUS TRANSPLANTATION VS CYCLOPHOSPHAMIDE-LENALIDOMIDE-DEXAMETHASONE AT DIAGNOSIS 49
BCR-ABL residues interacting with ponatinib are critical to preserve the tumorigenic potential of the oncoprotein 49
Multiple Myeloma Treatment in Real-world Clinical Practice: Results of a Prospective, Multinational, Noninterventional Study 49
Bone turnover markers in patients with type 1 Gaucher disease 49
HIGH-RESOLUTION SNP ARRAYS AS AN ADDITIONAL TOOL TO SEARCH FOR GENETIC DEFECTS INVOLVED IN PROGRESSION FROM MYELODYSPLASTIC SINDROME TO ACUTE LEUKEMIA 48
Follicular Lymphoma International Prognostic Index 2: A New Prognostic Index for Follicular Lymphoma Developed by the International Follicular Lymphoma Prognostic Factor Project 48
Effects of second-generation tyrosine kinase inhibitors towards osteogenic differentiation of human mesenchymal cells of healthy donors 48
Uncommon long-term survival in a patient with chronic myeloid leukemia 48
Absolute Count of Myeloid Derived Suppressor Cells (MDSC) Is Able to Predict the Response to Early-PET In Hodgkin Lymphoma 48
Detection of fungal dna in lysis-centrifugation blood culture for the prevision of response to antifungal in aml patients with persistent neutropenic fever: a pilot subset 48
Antitumor activity of bortezomib alone and in combination with TRAIL in human acute myeloid leukemia 48
The Apoptotic Machinery As A Biological Complex System: Analysis Of Its Omics And Evolution, Identification Of Candidate Genes For Fourteen Major Types Of Cancer And Experimental Validation in CML And Neuroblastoma 48
Angiogenesis in hematology: a field of active research 47
Angiogenesis in acute myeloid leukemia 47
Use of the word "cured" for cancer patients-implications for patients and physicians: the Siracusa charter 47
M4 acute myeloid leukemia: the role of eosinophilia and cytogenetics in treatment response and survival.THE GIMEMA EXPERIENCE 47
In vitro sensitivity of B-CLL cells to Fludarabine and Interferons 47
CD49d prevails over the novel recurrent mutations as independent prognosticator of overall survival in chronic lymphocytic leukemia. 47
Aberrant phenotypic expression of the T-cell-associated antigen CD8 on B-cell chronic lymphocytic leukemia cells 47
Phase II Multicentric Explorative Study of Intermittent Imatinib (IM) Treatment (INTERIM) in Elderly Patients with Ph+ Chronic Myeloid Leukemia (CML) Who Achieved a Stable Complete Cytogenetic Response (CCgR) with Standard IM Therapy 47
A Phase II Study of Chlorambucil Plus Rituximab Followed by Maintenance Versus Observation In Elderly Patients with Previously Untreated Chronic Lymphocytic Leukemia: Results of the First Interim Analysis 47
BCR-ABL Tyrosine Kinase Activity Modulates the Phosphorylation, Localization and Function of Interferon Regulatory Factor 5 (irf-5) in Chronic Myeloid Leukemia (CML) Cells 47
Il Rasario. Semeiotica medica 47
IRF5 is a target of BCR-ABL kinase activity and reduces CML cell proliferation. 47
Antitumor Activity of Bortezomib Alone and in Combination with TRAIL in Human Acute Myeloid Leukemia 47
PMN-MDSC and arginase are increased in myeloma and may contribute to resistance to therapy 47
Low dose of ARA-C in chronic myeloid leukemia in blastic transformation. 46
Chitotriosidase Expression during Monocyte-Derived Dendritic Cells Differentiation and Maturation 46
Mesenchymal Stem Cells (MSC) Regulate Activation of Granulocyte-Like Myeloid Derived Suppressor Cells (G-MDSC) in Chronic Myeloid Leukemia Patients 46
Salvage therapy with Thalidomide for patients with relapsed/refractory multiple myeloma 46
Acute myeloid leukemia in elderly patients. 46
Different in vitro alemtuzumab induced apoptosis on T and B lymphocytes of B-CLL patients 46
Alpha in- terferon as first line therapy for angioimmunoblastic lymphoadeno- pathy. Prognostic role of activated T-lymphocities. 46
IMATINIB INCREASES CYTOTOXICITY OF MELPHALAN AND DECREASES PROLONGATION OF G2-M PHASE IN HUMAN K562 CELLS 46
Efficacy of Dasatinib in a Very Elderly CML Patient Expressing a Rare E13a3 Bcr-Abl1 Fusion Transcript: A Case Report 46
Iron regulates myeloma cell/macrophage interaction and drives resistance to bortezomib 46
Totale 5.845
Salva come PNG Salva come JPEG
Categoria #
all - tutte 86.666
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 86.666
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2018/2019137 0 0 0 0 0 0 0 0 0 0 14 123
2019/20204.287 1.580 208 404 140 433 58 326 21 439 34 453 191
2020/20214.051 39 397 581 81 1.210 68 551 13 487 8 436 180
2021/20225.309 657 783 22 44 893 42 782 180 542 28 123 1.213
2022/20237.666 767 284 104 521 735 1.425 23 1.315 2.039 63 279 111
2023/20242.100 215 439 135 261 142 523 68 212 18 86 1 0
Totale 25.719